MAMorayo G. Adebiyi

Morayo G. Adebiyi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Morayo G. Adebiyi has a total of 4 co-authors. Here are the top co-authors by number of shared publications:

  • Jeanne M. Manalo

    Affiliations Department of Biochemistry and Molecular Biology, The University of Texas McGovern Medical School, Houston, Texas, United States of America, University of Texas MD Anderson UTHealth Graduate School of Biomedical Sciences, Houston, Texas, United States of America

    2 shared publications
  • Rodney E. Kellems

    Department of Biochemistry and Molecular Biology, The University of Texas McGovern Medical School, Houston, TX, USA; The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA

    1 shared publication
  • Yang Xia

    Department of Biochemistry and Molecular Biology, University of Texas McGovern Medical School, Houston, TX; and

    1 shared publication
  • Yang Xia

    Central South University, Xiangya hospital

    1 shared publication

Latest Publications

  • Differential role of adenosine signaling cascade in acute and chronic pain

    by Morayo G. Adebiyi, Jeanne Manalo, Rodney E. Kellems, Yang Xia


  • Metabolomic and molecular insights into sickle cell disease and innovative therapies

    by Morayo G. Adebiyi, Jeanne M. Manalo, Yang Xia

    Sickle cell disease (SCD) is an autosomal-recessive hemolytic disorder with high morbidity and mortality. The pathophysiology of SCD is characterized by the polymerization of deoxygenated intracellular sickle hemoglobin, which causes the sickling of erythrocytes. The recent development of metabolomics, the newest member of the “omics” family, has provided a powerful new research strategy to accurately measure functional phenotypes that are the net result of genomic, transcriptomic, and proteomic changes. Metabolomics changes respond faster to external stimuli than any other “ome” and are especially appropriate for surveilling the metabolic profile of erythrocytes. In this review, we summarize recent pioneering research that exploited cutting-edge metabolomics and state-of-the-art isotopically labeled nutrient flux analysis to monitor and trace intracellular metabolism in SCD mice and humans. Genetic, structural, biochemical, and molecular studies in mice and humans demonstrate unrecognized intracellular signaling pathways, including purinergic and sphingolipid signaling networks that promote hypoxic metabolic reprogramming by channeling glucose metabolism to glycolysis via the pentose phosphate pathway. In turn, this hypoxic metabolic reprogramming induces 2,3-bisphosphoglycerate production, deoxygenation of sickle hemoglobin, polymerization, and sickling. Additionally, we review the detrimental role of an impaired Lands’ cycle, which contributes to sickling, inflammation, and disease progression. Thus, metabolomic profiling allows us to identify the pathological role of adenosine signaling and S1P-mediated erythrocyte hypoxic metabolic reprogramming and hypoxia-induced impaired Lands' cycle in SCD. These findings further reveal that the inhibition of adenosine and S1P signaling cascade and the restoration of an imbalanced Lands' cycle have potent preclinical efficacy in counteracting sickling, inflammation, and disease progression.